๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seoul
Clinical trial register · South Korea

Clinical Trials in Seoul, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3364 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:49 UTC
3364
Studies in scope
all four open statuses
1829
Recruiting now
open to new participants
503
Lead sponsors
across recruiting studies
Top sites
Seoul 2820 Daegu 550 Seongnam-si 485 Busan 464 Goyang-si 395
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Seoul National University Hospital187 Yonsei University147 Samsung Medical Center142 Merck Sharp & Dohme LLC112
Site location
Seoul2820 Daegu550 Seongnam-si485 Busan464 Goyang-si395
All 252 locations
Target enrolment
to

Trials with a site in Seoul

2820 of 3364 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Evaluation of the Effectiveness and Safety of Remote Electrocardiographic Monitoring in Patients with Atrial Fibrillation Following Ablation Therapy
NCT06751459Atrial Fibrillation (AF)
HUINNO Co., Ltd
Not applicable
270
Busan, Seongnam, Seoul
2025-01-06
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
DrugR-DXd
Daiichi Sankyo
Phase 2
335
Goyang-si, Seoul
2025-01-06
Recruiting
To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers
NCT06703710Healthy
JW Pharmaceutical
Phase 1
72
Seoul
2025-01-06
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugPirtobrutinib
Loxo Oncology, Inc.
Phase 2
249
Busan, Hwasun-gun, Seoul
2025-01-03
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
DrugsVedolizumab·Upadacitinib
Takeda
Phase 3
396
Busan, Daegu, Daejeon, Seoul, Suwon
2025-01-02
Active, closed
Effectiveness of a Mobile Health Management Program for Colorectal Cancer Survivors With Chronic Conditions
NCT06759844Diabetes Mellitus, Colo-rectal Cancer, Hypertension, Dyslipidemia
Seoul National University Hospital
Not applicable
200
Seoul
2025-01-01
Not yet open
Digital CBT-I for Chronic Insomnia
NCT06695000Insomnia Chronic, Insomnia Disorder
WELT corp
Not applicable
120
Goyang-si, Yongin-si, Seoul
2025-01
Recruiting
Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator
NCT06696235Cardiogenic Shock, Acute Kidney Injury
Samsung Medical Center
Phase 4
408
Seoul
2024-12-31
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
DrugPembrolizumab
Alnylam Pharmaceuticals
Phase 1
158
Busan, Seongnam, Seoul
2024-12-30
Active, closed
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytrudaยฎ in Non-small Cell Lung Cancer (BENITO Study)
NCT06687369Non Squamous Non Small Cell Lung Cancer
DrugsEU sourced Keytruda·US-sourced Keytruda·Pemetrexed·Cisplatin
mAbxience Research S.L.
Phase 3
726
Busan, Gyeonggi-do, Incheon, Seoul
2024-12-30
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib
Janssen Research & Development, LLC
Phase 1
120
Seoul
2024-12-30
Recruiting
Robot-Assisted Neurovascular Intervention
NCT06752096Stroke, Meningioma, Neurovascular Disorder
Navigantis Inc.
Not applicable
10
Seoul
2024-12-27
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
Seongnam-si, Gyeonggi-do, Seoul, Suwon-si Gyeonggi-do, Suwon-si, Gyeonggi-do
2024-12-26
Recruiting
Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction
NCT07431008Erectile Dysfunction
Pharmicell Co., Ltd.
Observational
32
Seoul
2024-12-26
Recruiting
Research on the Relationship Between Scoliosis, Pain, Quality of Life, and Trunk Muscle Compensation Patterns Among Patients with Duchenne Muscular Dystrophy.
NCT06755138Duchenne Muscular Dystrophy (DMD)
Seoul National University Hospital
Observational
30
Seoul
2024-12-24
Recruiting
Clinical Outcomes of Edwards Lifesciences MITRIS RESLILA Mitral Valve in the Asian Population
NCT06757049Mitral Valve Insufficiency
Asan Medical Center
Observational
200
Seoul
2024-12-20
Active, closed
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06604715Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
17
Seoul
2024-12-19
Recruiting
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
NCT06797336Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
240
Seongnam, Seoul
2024-12-19
Active, closed
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
NCT06718101Atopic Dermatitis
DrugLutikizumab
AbbVie
Phase 2
83
Ansan-si, Bucheon-si, Seoul
2024-12-19
Recruiting
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
NCT06695026Hepatocellular Carcinoma (HCC)
DrugsRZ-001 1·RZ-001 2·RZ-001 3
Rznomics, Inc.
Phase 1/2
45
Busan, Daegu, Seoul
2024-12-18
Recruiting
Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children
NCT06742268Myopia
S-Alpha Therapeutics, Inc.
Observational
40
Seoul, Hwaseong-si, Gwangmyeong, Incheon
2024-12-16
Recruiting
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
NCT06501625Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
DrugsIvosidenib·Durvalumab·Gemcitabine·Cisplatin
Institut de Recherches Internationales Servier
Phase 1/2
52
Seongnam, Seoul
2024-12-16
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Hwasun, Jeonju, Seoul, Ulsan
2024-12-16
Recruiting
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
170
Goyang-si, Seoul
2024-12-16
Not yet open
This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants
NCT06736912Chronic Idiopathic Constipation
HK inno.N Corporation
Phase 1
80
Seoul
2024-12-16
Recruiting
Study of Ultomirisยฎ (Ravulizumab) Safety in Pregnancy
NCT06312644Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
DrugUltomiris
Alexion Pharmaceuticals, Inc.
Observational
75
Seoul
2024-12-16
Recruiting
Stress Urinary Incontinence for Female Patients (CGM MUIT-2301)
NCT07440927Stress Urinary Incontinence (SUI)
Ceragem Clinical Inc.
Not applicable
96
Seoul
2024-12-13
Active, closed
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma
DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine
Arcus Biosciences, Inc.
Phase 3
610
Hwasun, Seongnam, Seoul
2024-12-13
Active, closed
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT06710847Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer
GlaxoSmithKline
Phase 1/2
14
Daegu, Gyeonggi-do, Seoul
2024-12-13
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Irinotecan·Cetuximab
Janssen Research & Development, LLC
Phase 3
700
Daegu, Seoul
2024-12-12
Recruiting
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
NCT06647550Type 2 Diabetes Mellitus (T2DM)
Hyundai Pharm
Phase 2
160
Seoul
2024-12-12
Active, closed
Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
NCT06926933CPP
DrugEligard
HanAll BioPharma Co., Ltd.
Phase 4
50
Ansan, Jeonju, Kwangju, Seongnam, Seoul, Suwon
2024-12-12
Recruiting
Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
NCT06537193Hepatocellular Carcinoma
Asan Medical Center
Not applicable
455
Seoul
2024-12-12
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606Connective Tissue Diseases
DrugBelimumab
GlaxoSmithKline
Phase 3
514
Bucheon Kyunggi-Do, Seoul, Suwon Kyunggi-do, Yongsan-Ku Seoul
2024-12-12
Recruiting
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
NCT06516679Leukemia, Lymphoid
DrugDaunorubicin
Yonsei University
Phase 2
40
Daegu, Daejeon, Hwasun, Jeju City, Pusan, Seoul
2024-12-11
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Daegu, Seoul, Suwon
2024-12-11
Recruiting
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT06724016Advanced or Metastatic Solid Tumors
DrugsKeytruda·Pembrolizumab
Hanmi Pharmaceutical Company Limited
Phase 1
292
Seongnam-si, Seoul
2024-12-11
Recruiting
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
NCT06667453Myotonic Dystrophy 1
DrugPGN-EDODM1
PepGen Inc
Phase 2
24
Pusan, Daegu, Seoul
2024-12-10
Recruiting
Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
NCT06944457Cancer, Solid Tumor Cancer, Biomarkers
Pharosgen Co.,Ltd
Phase 1
24
Seoul
2024-12-10
Recruiting
Validation of the Prognostic Impact of a Retinal Photograph-based Cardiovascular Disease Risk Stratification System in de Novo HFrEF
NCT06978998Heart Failure, Cardiomyopathies, Retinal Photograph, Deep Learning
Yonsei University
Observational
100
Seoul
2024-12-10
Recruiting
Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers
NCT06736587Autoimmune Diseases
Daewoong Pharmaceutical Co. LTD.
Phase 1
84
Seoul
2024-12-10
Recruiting
Effect of Preemptive Education on the Incidence of Maternal Intraoperative Shivering in Elective Cesarean Delivery
NCT06708169Shivering, Spinal Anesthesia
Seoul National University Hospital
Not applicable
130
Seoul
2024-12-09
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
BundangGu SeongnamSi, Seongnam-si, BukGu, NamdongGu, GangnamGu, SeodaemunGu, Seoul, SongpaGu
2024-12-09
Recruiting
The Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Pain and Recovery in Children (< 7 Years Old) Undergoing Thoracoscopic Surgery
NCT06710405Pain Management After Surgery
DrugLidocaine
Seoul National University Hospital
Phase 4
80
Seoul
2024-12-09
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Daejeon, Goyang-si, Gyeonggi-do, Seongnam-si, Gyeonggi-do, Seoul
2024-12-09
Active, closed
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB
Phase 2
378
Bucheon-si, Busan, Goyang-si, Seoul
2024-12-09
Active, closed
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983Muscle-invasive Urothelial Carcinoma
DrugsAutogene Cevumeran·Nivolumab
Hoffmann-La Roche
Phase 2
62
Seongnam-si, Seoul
2024-12-09
By invitation
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
NCT07064525Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure, Diabete Mellitus
Shin Poong Pharmaceutical Co. Ltd.
Phase 2
252
Seoul
2024-12-05
Active, closed
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
NCT06712615Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
DrugPG-102
ProGen. Co., Ltd.
Phase 2
144
Bucheon-si, Daegu, Daejeon, Seongnam, Seoul
2024-12-05
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Gwangju, Seongnam-si, Seoul, Suwon
2024-12-04
Recruiting
Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition
NCT06625957Parenteral Nutrition
Yuhan Corporation
Phase 3
60
Gyeonggi-do, Jeollanam-do, Jeollabuk-do, Seoul
2024-12-04
Recruiting
Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
NCT06647888Diabetes Mellitus, Type 2
DrugsEnvlomet·Envlo·Enavogliflozin
Daewoong Pharmaceutical Co. LTD.
Observational
12,000
Seoul
2024-12-03
Recruiting
Efficacy of RUS GA Surgical Navigation for Robot-assisted Distal Gastrectomy in Gastric Cancer Patients
NCT06639490Gastric Cancer
Yonsei University
Not applicable
330
Seoul
2024-12-03
Active, closed
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622Multiple System Atrophy
DrugAmlenetug
H. Lundbeck A/S
Phase 3
401
Seoul
2024-12-03
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Seoul
2024-12-03
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698Chronic Kidney Disease
DrugSemaglutide
Novo Nordisk A/S
Phase 2
465
Goyang-si, Busan, Gyeonggi-do, Seoul
2024-12-02
Recruiting
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700Coronavirus Disease (COVID-19)
DrugMolnupiravir
Merck Sharp & Dohme LLC
Phase 3
3,082
Wลnju, Gwangju, Ansan-si, Jinju, Pusan, Deagu, Seoul
2024-12-02
Recruiting
Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
NCT06643130Hypertension, Dyslipidemia
JW Pharmaceutical
Phase 3
162
Seoul
2024-12-02
By invitation
Implementation of the ERAS in Colorectal Cancer Patients: a Single Arm Study
NCT06729736Colorectal Cancer
Seoul National University Hospital
Not applicable
500
Seoul
2024-12-01
By invitation
Comparing Immediate Removal and Postoperative 1 Day of Urinary Catheter After Colorectal Cancer Surgery
NCT06769087Colorectal Cancer, Postoperative Complication, Urinary Retention Postoperative, Enhanced Recovery After Surgery
Seoul St. Mary's Hospital
Not applicable
316
Seoul
2024-12-01
Recruiting
Tegoprazan- Versus PPI-based H. Pylori Eradication
NCT06682533H.Pylori Infection
Soonchunhyang University Hospital
Observational
200
Seoul
2024-12-01
Active, closed
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754Hereditary Angioedema (HAE)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
81
Daegu, Seoul, Suwon
2024-12-01
Recruiting
Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer
NCT06767449Advanced Gastric Cancer
Yonsei University
Observational
80
Seoul
2024-12-01
Active, closed
Head Position Monitoring After Pars Planar Vitrectomy
NCT06985030Retinal Detachment, Macular Hole
Seoul National University Hospital
Observational
100
Seoul
2024-11-28
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin
AstraZeneca
Phase 3
1,160
Gyeonggi-do, Seoul, Songpa-gu
2024-11-27
Active, closed
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT06428396Metastatic Breast Cancer
DrugsBelzutifan·Exemestane·Everolimus·Fulvestrant
Merck Sharp & Dohme LLC
Phase 2
120
Seoul
2024-11-27
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Seoul
2024-11-27
Recruiting
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
NCT06645678Relapsed Refractory Multiple Myeloma (RRMM)
DrugsMezigdomide·Elranatamab·Dexamethasone
YOUNGIL KOH
Phase 1/2
75
Hwasun, Seoul
2024-11-26
Active, closed
Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy
NCT06552572Diffuse Large B Cell Lymphoma
DrugGlofitamab
Samsung Medical Center
Phase 2
30
Seoul
2024-11-26
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Suwon, Cheongju-si, Daegu, Goyang-si, Seoul
2024-11-25
Recruiting
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
NCT06737250Primary CNS Lymphoma (PCNSL)
NOBO Medicine
Phase 2
33
Busan, Hwasun, Ilsan, Seongnam, Seoul, Ulsan
2024-11-25
Recruiting
Phase 1 Single Ascending Dose Study
NCT06934941Healthy Subjects
Neuramedy Co. Ltd.
Phase 1
36
Seoul
2024-11-25
Recruiting
Validation Study of CART BP as a Wearable Cuffless Blood Pressure Monitor
NCT06513975Blood Pressure, Hypertension, Blood Pressure, High, Blood Pressure, Low
Sky Labs
Not applicable
50
Seoul
2024-11-22
Recruiting
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498Alzheimers Disease, Dementia, Alzheimers Disease, Familial
DrugRemternetug
Washington University School of Medicine
Phase 2/3
280
Seoul
2024-11-22
Recruiting
A Phase โ…ข Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
DrugsHLX22·Trastuzumab·Capecitabine·Oxaliplatin
Shanghai Henlius Biotech
Phase 3
550
Cheongju-si, Jinju, Seoul
2024-11-22
Recruiting
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157Alzheimers Disease, Dementia, Alzheimers Disease, Familial
DrugRemternetug
Washington University School of Medicine
Phase 2/3
280
Seoul
2024-11-22
Active, closed
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
NCT06567769Sanfilippo Syndrome Type A
GC Biopharma Corp
Phase 1
9
Suwon, Seoul
2024-11-21
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Busan, Incheon, Seoul, Suwon
2024-11-21
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
67
Pusan Kwangyokshi, Daejeon, Seoul
2024-11-21
Recruiting
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
NCT06627322Type 2 Diabetes
Kyu Chang Won
Not applicable
5,950
Daegu, Seoul
2024-11-21
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
DrugsTORL-1-23·Pegfilgrastim
TORL Biotherapeutics, LLC
Phase 2
230
Seoul
2024-11-20
Recruiting
GIST Oral Paclitaxel(Liporaxel)
NCT06326346Gastrointestinal Stromal Tumors
DrugLiporaxel
Asan Medical Center
Phase 2
28
Seoul
2024-11-20
Recruiting
Prediction of Atrial Fibrillation Using Polygenic Risk Score
NCT07641582Atrial Fibrillation (AF)
Seoul St. Mary's Hospital
Not applicable
800
Incheon, Seoul, Suwon, Uijeongbu-si
2024-11-19
By invitation
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovyยฎ (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
NCT07018544Obesity and Overweight
Novo Nordisk A/S
Observational
840
Goyang-si, Busan, Chungcheongnam-do, Daejeon, Gyeonggi-do, Seoul, Yangsan
2024-11-19
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Busan, Daegu, Hwasun-gun, Incheon, Jeonju, Seongnam-si, Seoul, Suwon
2024-11-19
By invitation
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
NCT06435312Generalized Myasthenia Gravis
DrugZilucoplan
UCB Biopharma SRL
Phase 3
8
Seoul
2024-11-19
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
125
Seongnam-si, Seoul
2024-11-18
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Changwon-si, Cheongju-si, Incheon, JinJoo, Seoul, Suwon
2024-11-18
Recruiting
Registry Study on Rare Cancers in Korea
NCT06746766Rare Cancer
Yonsei University
Observational
500
Seoul
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Seoul, Ulsan, Busan
2024-11-15
Recruiting
A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
NCT06555432Cytomegalovirus (CMV)
DrugMaribavir
Takeda
Observational
168
Seoul
2024-11-14
Recruiting
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
NCT06644755Solid Tumors, Sarcoma
Daiichi Sankyo
Phase 1
150
Seoul
2024-11-14
Recruiting
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT06619587Solid Tumor
Genentech, Inc.
Phase 1
410
Seongnam, Seoul
2024-11-14
Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects
NCT06635226Healthy Adult Subjects
IlDong Pharmaceutical Co Ltd
Phase 1
36
Seoul
2024-11-13
Not yet open
Individualized Automatic Coaching Message for Glycemic Management and Depressive Symptom
NCT06684678Diabetes Mellitus, Type 1, Continuous Glucose Measurement
Samsung Medical Center
Not applicable
140
Seoul
2024-11-13
Recruiting
Development and Validation of a Personalized Digital Healthcare Model for Managing Side Effects in Breast Cancer Survivors
NCT06729684Breast Cancer Survivorship, Breast Cancer, Digital Health
Samsung Medical Center
Not applicable
72
Seoul
2024-11-13
Recruiting
LIVERAGEโ„ข - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Bucheon-si, Busan, Incheon, Seoul, Wลnju
2024-11-12
Recruiting
A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)
NCT07252323Carcinoma, Hepatocellular Carcinoma
Yonsei University
Not applicable
48
Seoul
2024-11-12
Active, closed
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
283
Ansan, Busan, Pusan, Seoul
2024-11-11
Active, closed
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT06614192Metastatic Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
74
Seongnam-si, Seoul
2024-11-08
Rows per page Showing 1001–1100 of 2820
Previous 9 10 11 12 13 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seoul?page=11

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,364 studies in total at the last sync on 26 Sep 2026, 19:49 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,820 of those studies with a site in Seoul.

How many clinical trials are recruiting in Seoul?

1,518 of the 2,820 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:49 UTC sync. A further 209 have not yet opened recruitment, 1,015 are active but closed to new participants, and 78 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.